ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub

BidaskClub lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a report published on Thursday.

A number of other research analysts also recently commented on the stock. ValuEngine downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, December 20th. Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the company a buy rating in a report on Saturday, December 9th. TheStreet raised shares of ANI Pharmaceuticals from a c+ rating to a b rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 price objective on the stock in a research report on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $70.50.

ANI Pharmaceuticals (NASDAQ:ANIP) opened at $63.38 on Thursday. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals has a 1-year low of $42.23 and a 1-year high of $74.70. The company has a market cap of $737.94, a PE ratio of 100.60 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. During the same quarter last year, the firm earned $1.09 EPS. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. research analysts expect that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of ANIP. Schwab Charles Investment Management Inc. raised its position in ANI Pharmaceuticals by 36.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 38,906 shares of the specialty pharmaceutical company’s stock worth $1,927,000 after purchasing an additional 10,489 shares during the period. Municipal Employees Retirement System of Michigan increased its position in shares of ANI Pharmaceuticals by 132.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after acquiring an additional 2,390 shares during the period. Great West Life Assurance Co. Can increased its position in shares of ANI Pharmaceuticals by 8.6% during the second quarter. Great West Life Assurance Co. Can now owns 12,614 shares of the specialty pharmaceutical company’s stock worth $590,000 after acquiring an additional 1,000 shares during the period. Texas Permanent School Fund increased its position in shares of ANI Pharmaceuticals by 1.9% during the second quarter. Texas Permanent School Fund now owns 5,863 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 111 shares during the period. Finally, State of Wisconsin Investment Board purchased a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $281,000. 55.05% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/25/ani-pharmaceuticals-anip-downgraded-to-hold-at-bidaskclub.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

What are top analysts saying about ANI Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ANI Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit